BSI Capital Group

BSI Capital is a Single Family Office based in Mexico City Mexico. The firm is looking to make growth stage investments into healthcare companies generally in series C and D rounds or later. Due to the structure of the firm BSI has a highly variable investment size that will depend of the financial needs of the company. The firm is currently looking for new opportunities throughout the United States Mexico and Canada. The firm has no set number of investment in plans to make over the next 6-9 months.
Alejandra Paradones
CEO & Founder 

California Institute for Regenerative Medicine (CIRM)

The California Institute for Regenerative Medicine (CIRM) was established in 24 with the passage of Proposition 71 and is based in San Francisco California. Proposition 71 provided for $3 billion for CIRM to fund stem cell research in the state of California. CIRM provides strictly non-dilutive funding in the forms of research grants and forgivable loans the largest of which provide for up to $2 million of funding. Being motivated partially by the economic development of California the firm is interested in companies located in California or those that have an interest in relocating or opening space in California.
Neil Littman
Business Development Officer 

CDRD Ventures Canada

CDRD Ventures Inc. (CVI) is the commercialization vehicle of the Centre for Drug Research and Development (CDRD), Canada's national drug development and commercialization center that was founded in 2007 and is based in Vancouver, Canada. CVI seeks to advance promising drug development projects from CDRD using internal funds and through partnerships with international pharmaceutical companies, venture capital firms, biotech companies, and other funding agencies. CVI also seeks to in-license technologies from industry or non-CDRD affiliated research institutions. The firm considers both small molecule and biologic innovative technologies in virtually any therapeutic area.

Ms Natalie Dakers
President & CEO 
Mr Michael Lincoln
Chief Financial and Business Officer 

Chiesi Ventures

Chiesi Ventures is a Venture Capital firm formed by a partnership between the Italian Pharmaceutical company Chiesi and US based VC firm Pappas Ventures. The firm is currently looking to make seed and venture stage investments into companies ranging anywhere from $2K to $5 million initially and up to $8 million over the life of the investment. The firm is actively seeking investment opportunities throughout the United States and Europe and could make as many as 2-4 new investments over the next year.
Art Pappas
Partner 

CitareTx Investment Partners

CitareTx founded in 2008 is a venture development and investment firm based in Houston Texas. The firm provides investment and incubation services to start-up and early-stage medical device companies. The firm provides seed capital (equity) ranging from $5K to $2M with follow-on capital of up to $5M. The firm also considers investment opportunities with smaller than typically accepted venture capital market size thresholds. The firm is geographically agnostic but prefers companies to be based in Texas. The firm is actively seeking new opportunities.

Jeffery Sheldon
General Partner & Managing Director 

Clayton Biotechnologies United States

Clayton Biotechnologies commercializes technologies that are developed and owned by the Clayton Foundation for Research and its supporting entities through research programs at leading research hospitals and institutions in the US and Switzerland.

We have several projects in various stages of development from discovery to advanced pre-clinical that are available for licensing, collaboration, and the creation of new start-up ventures.

Clayton Biotechnologies has a significant portfolio of technologies to offer for licensing and collaboration. 

 

Some of our featured technologies:

- Urocortins and analogues for Diabetes

- Fc engineering of aglycosylated antibodies

- Granzyme B - a potent payload for antibody drug conjugates (ADC)

- Alk4-Fc, a Cripto antagonist for Cancer

- TEAD gene and peptide therapies for ocular neovascular disease

- Stem cell therapy program for Parkinson's Disease

- Vaccines and Diagnostics for Ehrlichioses

- Biomarker for personalized breast cancer therapy

- YESS - engineering of proteases

- OCT Image Guided Smart Laser Knife Diagnosis and Therapy in Small Spaces

 

To date, 9 products based on Clayton Foundation discoveries have been have been successfully commercialized through the creation of start-up companies and out-licensing

Alexandra Richardson
Head of Business Development 

Colorado Institute for Drug Device and Diagnostic Development United States

The Colorado Institute for Drug, Device and Diagnostic Development (CID4) is a 501(c)3 not-for-profit entity committed to economic development through the creation and funding of Colorado Life Science companies. Our goal is to efficiently transform emerging life science innovations into commercial successes. First, we use a rigorous review process and advisory panel to select promising post-proof-of-concept technologies from Colorado’s outstanding research institutions and start-up companies. Second, we fund and actively manage product development while taking an equity position in existing companies and in new companies that we found with the inventors. Third, we facilitate additional seed and/or grant funding to further develop our portfolio companies technologies. By augmenting the value of these innovations, we position our portfolio companies to attract series A financing from venture capitalists and/or partnering opportunities with established pharmaceutical and biotechnology companies. We have funded 9 early stage companies since June 2010 and these companies have raised more than $30 million in additional private capital and grant funding.

Website:
www.cid4.com
Year Founded
2009
Biotech Phase of Development
Technology Overview
CID4 has 9 portfolio companies and several project companies that it represents. The companies and technologies are: Sophono (marketed bone anchored hearing device); PeptiVir (pre-clinical stage, peptide-based vaccine platform for influenza, MERS, Ebola, RSV and HIV); Flashback (CipherSensor algorithm for use in medical devices that monitor vital signs); VetDC (FDA approved veterinary oncology product); KromaTiD (molecular diagnostics to detect chromosomal inversion mutations); Aurora Oncology (IND ready bladder cancer therapies); aktiVax (post-protoype, pre-filled syringes and biocompatible vial replacements); Fitbionic (marketed foot prostheses); Sapphire Technologies (post-prototype non-stick dental device for packing composite materials); ApopLogic (phase 1 lung cancer drug; IND-ready targeted biologic for cancer); MenoGeniX (phase 2 menopause hot flash therapy)
Alliance & Collaborations
Colorado Office of Economic Development, Fitzsimons Redevelopment Authority, SBA, Colo. BioSciences Assn., High Country Venture, CU, CSU Ventures
Supporting Metrics or Evidence
Since June 2010: (1) >150 companies reviewed by our technical and business advisory committee; (2) Technology and IP from public research institutions and private companies; (3) $3 million invested in 9 companies (2 started by CID4); (4) Our portfolio companies have raised an additional $30 million in follow-on financing and grants
Current Financing Needs
We are looking for $10 million in philanthropic, angel, corporate and/or venture funding to match $5 million in available State of Colorado ED grant funds
Current Timeline
N/A
Current Investors
Colorado Office of Economic Dev. ($5.1 million), Fitzsimons Redevelopment Authority ($1 million)
IP Status
All of our companies have issued patents
Recent Milestones
Completed our 9th investment.
Management Team Highlights
Our management team has an average of over 30 years in the biotechnology and medical device industry in both start-up and large companies
Richard Duke
Founder & CSO 

Correlation Ventures United States

Correlation Ventures is a venture capital firm that founded in 2010 and is based in San Diego, California with an additional office in Palo Alto, California. The firm currently has approximately $165 million in total assets under management. The firm typically makes investments ranging from $0.25 million to $5 million over the life of the company, and the first investment will be not larger than $2.5 million. The firm’s preferred capital structure is convertible preferred equity or convertible loan. Correlation Ventures will consider invest in any industry segment at any stage, but there must be at least one other venture capital firm making their first investment in the company in this round. The firm only invests in US-based companies. 

Correlation is extremely opportunistic when it comes to investments in the life sciences space; with that being said the firm's specified sectors and sub sectors of interest may or may not be an area in which Correlation Ventures is currently looking to allocate capital to. The firm has made a number of investments in companies in the life sciences space, and has mainly invested in companies in the biotech therapeutics and diagnostics space. The firm's current portfolio includes biotech therapeutics and diagnostics firms developing products targeting endocrine, metabolic, and nutritional diseases, musculoskeletal system and connective tissue, neoplasms, cancer, and oncology, genitourinary system, and infectious and parasitic diseases.

Year Founded
2010
Investor Type
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
David Coats
Managing Director 

Deep Knowledge Ventures Hong Kong SAR China

We are a Hong Kong-based venture fund management company focusing on mid- to long-term advanced technology investments at early stage. Through our partnership with the top analytical companies utilizing machine learning and large panel of experts, we can construct complex decision trees showing risk and return at every stage of company evolution. We routinely invest in both private and public companies specializing in biotechnology, drug discovery, personalized medicine, Big Data analysis, industrial expert systems and artificial intelligence. 

Mr Charles Groome
Mr Charles Groome
LinkedIn logo Venture Partner 
Mr Dmitry Kaminskiy
Mr Dmitry Kaminskiy
LinkedIn logo Senior Partner 

Diamond BioFund Taiwan

Diamond BioFund is an evergreen fund that was established in 2013 and is based in Taipei City, Taiwan. The fund is operating from a committed capital of USD 300 million. The fund makes equity investments in early- to late-stage private businesses. Typical allocations range from USD 1.5 million to north of USD 10 million. The fund likes to lead investments in Taiwan-based businesses and co-invest in businesses overseas. The fund is currently seeking new opportunities in Taiwan, Greater China, Southeast Asia, US, Canada, and EU.

Diamond BioFund takes a generalist approach when considering life science opportunities, including therapeutics (small molecule and biologics), medical devices, diagnostics, healthcare services, and nutraceuticals. The fund is seeking cutting edge, innovative, and platform technology. In therapeutics, the fund considers all stages from preclinical through pre-IPO. In medical devices, the fund prefers later stage projects with proof of concept. The fund is open to all disease indications.

Investor Type
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Winston Town
Vice President 
Haolin Sung
LinkedIn logo Director